ODP246 The Content of Blood Chemokine Fractalkine in Patients with Type 2 Diabetes and Diabetic Macular Edema Depending on The Type of Glucose Lowering Therapy

Abstract

Diabetic macular edema (DME) remains one of the most widespread diabetic complications. Complications associated with DME include microglial activation, dysfunction of neurons, their dystrophy and apoptosis. One of the important modern chemokines involved in the functioning of the eye neurovascular unit is fractalkine (CX3CL1). The current literature has demonstrated a positive and significant relationship between fraktalkine aqueous humor levels and central macular thickness after intravitreal injection of aflibercept in patients with DME [Rodolfo Mastropasqua et al., 2018]. Goal. To evaluate the content of blood plasmachemokine fractalkine in patients with type 2 diabetes (T2D) and DME depending on the type of glucose lowering therapy (GLT). Conclusion: In patients undergoing insulin therapy, the content of fractalkine in blood plasma is statistically significantly (p = 0.02) higher than in patients receiving OGLD.